The Thread Formerly Known as No Rest For The Wicked Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Thread Formerly Known as No Rest For The Wicked

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jane4IceCream who wrote (49069)	6/4/1999 9:52:00 PM
From: Dave	Read Replies (2) of 90042

Jane, I like the biotechs you picked, however, it's important to keep in mind that biotech is still a very risky play as many products die sudden deaths in phase III trials, even ones that looked great in earlier stages. Getting cancer drugs approved is very dicey. It might be a good idea for the position player to bolster their portfolio with some of the big pharma movers. I agree completely that PFE is a great company with excellent future prospects. They have an excellent pipeline that will continue to keep them in "good earnings" for quite some time and are therefore not a one-product company. May want to check out HMR for a play on Enbrel as they market the drug. It seems to be doing well in the marketplace. FWIW, dave

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next